Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: Comparison of a nomogram to the Motzer criteria

European Urology

Volumn 60, Issue 1, 2011, Pages 48-56

  Karakiewicz, Pierre I ^a   Sun, Maxine ^a   Bellmunt, Joaquin ^b   Sneller, Vesna ^c   Escudier, Bernard ^d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HOSPITAL DEL MAR   (Spain)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bevacizumab; Metastatic; Nomogram; Prognostic factors; Progression free survival; Renal cell carcinoma

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BEVACIZUMAB; INTERFERON; PLACEBO;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC KIDNEY CARCINOMA; PHASE 3 CLINICAL TRIAL; PREDICTION; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALIDATION PROCESS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS;

EID: 79957947365     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.12.011     Document Type: Article

References (23)

1. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
2. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
3. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
4. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
5. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
6. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296 (Pubitemid 34032623)
7. V. Ficarra, M. Brunelli, and L. Cheng Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors Eur Urol 58 2010 655 668
8. M. Mazumdar, and J.R. Glassman Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments Statist Med 19 2000 113 132 (Pubitemid 30051256)
9. K. Lu, and A. Tsiatis Multiple imputation methods for estimating regression coefficients in the competing risks model with missing cause of failure Biometrics 57 2001 1191 1197 (Pubitemid 33108112)
10. T.G. Clark, and D.G. Altman Developing a prognostic model in the presence of missing data: an ovarian cancer case study J Clin Epidemiol 56 2003 28 37 (Pubitemid 36183312)
11. F. Harrell, K. Lee, and D. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387 (Pubitemid 26072233)
12. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771 (Pubitemid 28259189)
13. P.I. Karakiewicz, A. Briganti, and F.K.-H. Chun Multi-institutional validation of a new renal cancer-specific survival nomogram J Clin Oncol 25 2007 1316 1322 (Pubitemid 46706877)
14. E. DeLong, D. DeLong, and D. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
15. M. Sun, G. Lughezzani, and P. Perrotte Treatment of metastatic renal cell carcinoma Nat Rev Urol 7 2010 327 338
16. B. Escudier, L. Albiges, and A. Blesius How to select targeted therapy in renal cell cancer Ann Oncol 21 Suppl 7 2010 vii59 62
17. E. Herrmann, S. Bierer, and C. Wülfing Update on systemic therapies of metastatic renal cell carcinoma World J Urol 28 2010 303 309
18. A. Ravaud, H. Wallerand, and S. Culine Update on the medical treatment of metastatic renal cell carcinoma Eur Urol 54 2008 315 325
19. M. Sun, S.F. Shariat, and P.I. Karakiewicz Factors affecting outcome in renal cell carcinoma Curr Opin Urol 20 2010 355 360
20. B. Escudier, M.G. Goupil, and C. Massard Sequential therapy in renal cell carcinoma Cancer 115 2009 2321 2326
21. J. Sosman, and I. Puzanov Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2009 2368 2375
22. J. Medioni, E. Banu, and D. Helley Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series Eur Urol 56 2009 207 211
23. P. Royston, D.G. Altman, and W. Sauerbrei Dichotomizing continuous predictors in multiple regression: a bad idea Statist Med 25 2006 127 141 (Pubitemid 43136953)